title: Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma.
abstract: Elotuzumab is one of the first monoclonal antibodies to be approved for the treatment of multiple myeloma. It is a humanized immunoglobulin G kappa (IgGκ) antibody that targets signaling lymphocytic activation molecule family member 7 (SLAMF7), a surface marker that is highly expressed on normal and malignant plasma cells. This review summarizes the preclinical and clinical data that led to the approval of elotuzumab, along with a discussion on the ongoing and future clinical investigations.
authors.affiliation: Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Carolinas Healthcare System, UNC School of Medicine, Charlotte, NC, USA.
authors.forename: Reed
authors.initials: R
authors.lastname: Friend
authors.affiliation: Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Carolinas Healthcare System, UNC School of Medicine, Charlotte, NC, USA.
authors.forename: Manisha
authors.initials: M
authors.lastname: Bhutani
authors.affiliation: Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Carolinas Healthcare System, UNC School of Medicine, Charlotte, NC, USA.
authors.forename: Peter M
authors.initials: PM
authors.lastname: Voorhees
authors.affiliation: Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Carolinas Healthcare System, UNC School of Medicine, Charlotte, NC, USA.
authors.forename: Saad Z
authors.initials: SZ
authors.lastname: Usmani
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy*; D000071176:Signaling Lymphocytic Activation Molecule Family / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C448987:SLAMF7 protein, human; D000071176:Signaling Lymphocytic Activation Molecule Family; C546027:elotuzumab
keywords: CS1; SLAMF7; elotuzumab; multiple myeloma; refractory; relapsed; treatment